Brief: Spero Announces NDA Resubmission Of Tebipenem Hbr By Gsk To The FDA
19/12/2025 14:21
Dec 19 (Reuters) - Spero Therapeutics Inc SPRO.O: SPERO ANNOUNCES NDA RESUBMISSION OF TEBIPENEM HBR BY GSK TO THE FDA FOR THE TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING PYELONEPHRITIS SPERO THERAPEUTICS INC - NDA SUBMISSION TRIGGERS $25 MILLION MILESTONE PAYMENT TO SPERO Source text: ID:nGNX8k6H2j Further company coverage: SPRO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)